Page 28 - 87_01

dose-ranging trial. Journal of hepatology. 2013;58(4):663-8.
21. Ribaldone DG, Sacco M, Saracco GM. The Effect of Viral Clearance
Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive
Patients with Type 2 Diabetes Mellitus: A Word of Caution after the In-
itial Enthusiasm. Journal of clinical medicine. 2020;9(2).
22. Benedicto I, Molina-Jimenez F, Barreiro O, Maldonado-Rodriguez A,
Prieto J, Moreno-Otero R, et al. Hepatitis C virus envelope components
alter localization of hepatocyte tight junction-associated proteins and
promote occludin retention in the endoplasmic reticulum. Hepatology.
2008;48(4):1044-53.
23. Zhang W, Patil S, Chauhan B, Guo S, Powell DR, Le J, et al. FoxO1 re-
gulates multiple metabolic pathways in the liver: effects on gluconeo-
genic, glycolytic, and lipogenic gene expression. The Journal of
biological chemistry. 2006;281(15):10105-17.
24. Lee J, Kim MS. The role of GSK3 in glucose homeostasis and the de-
velopment of insulin resistance. Diabetes research and clinical practice.
2007;77 Suppl 1:S49-57.
25. Douglas MW, George J. Molecular mechanisms of insulin resistance in
chronic hepatitis C. World journal of gastroenterology.
2009;15(35):4356-64.
26. Fabrizio C, Procopio A, Scudeller L, Dell'Acqua R, Bruno G, Milano E,
et al. HCV and diabetes: towards a 'sustained' glycaemic improvement
after treatment with DAAs? Clinical microbiology and infection : the of-
ficial publication of the European Society of Clinical Microbiology and
Infectious Diseases. 2017;23(5):342-3.
27. Gastaldi G, Gomes D, Schneiter P, Montet X, Tappy L, Clement S, et al.
Treatment with direct-acting antivirals improves peripheral insulin sen-
sitivity in non-diabetic, lean chronic hepatitis C patients. PloS one.
2019;14(6):e0217751.
28. Huang JF, Huang CF, Yeh ML, Dai CY, Hsieh MH, Yang JF, et al. The
outcomes of glucose abnormalities in chronic hepatitis C patients re-
ceiving interferon-free direct antiviral agents. The Kaohsiung journal
of medical sciences. 2017;33(11):567-71.
29. Hum J, Jou JH, Green PK, Berry K, Lundblad J, Hettinger BD, et al. Im-
provement in Glycemic Control of Type 2 Diabetes After Successful Tre-
atment of Hepatitis C Virus. Diabetes care. 2017;40(9):1173-80.
30. Pavone P, Tieghi T, d'Ettorre G, Lichtner M, Marocco R, Mezzaroma I,
et al. Rapid decline of fasting glucose in HCV diabetic patients treated
with direct-acting antiviral agents. Clinical microbiology and infection:
the official publication of the European Society of Clinical Microbiology
and Infectious Diseases. 2016;22(5):462 e1-3.
31. Ciancio A, Bosio R, Bo S, Pellegrini M, Sacco M, Vogliotti E, et al. Sig-
nificant improvement of glycemic control in diabetic patients with HCV
infection responding to direct-acting antiviral agents. Journal of medical
virology. 2018;90(2):320-7.
32. Lim TR, Hazlehurst JM, Oprescu AI, Armstrong MJ, Abdullah SF, Davies
NP, et al. Hepatitis C virus infection is associated with hepatic and adi-
pose tissue insulin resistance that improves after viral cure. Clinical en-
Sofosbuvir Treatment Improves Hepatitis C Virus-Induced In-
26 sulin Resistance
Esther Rey, Patricia Marañón y Águeda González-Rodríguez
An. Real Acad. Farm. Vol. 87. Nº1 (2021) · pp. 15 - 26
ANALES
RANF
www.analesranf.com
docrinology. 2019;90(3):440-8.
33. Copps KD, White MF. Regulation of insulin sensitivity by serine/threo-
nine phosphorylation of insulin receptor substrate proteins IRS1 and
IRS2. Diabetologia. 2012;55(10):2565-82.
34. Bose SK, Shrivastava S, Meyer K, Ray RB, Ray R. Hepatitis C virus ac-
tivates the mTOR/S6K1 signaling pathway in inhibiting IRS-1 function
for insulin resistance. Journal of virology. 2012;86(11):6315-22.
35. Deng L, Shoji I, Ogawa W, Kaneda S, Soga T, Jiang DP, et al. Hepatitis
C virus infection promotes hepatic gluconeogenesis through an NS5A-
mediated, FoxO1-dependent pathway. Journal of virology.
2011;85(17):8556-68.
36. Shlomai A, Rechtman MM, Burdelova EO, Zilberberg A, Hoffman S,
Solar I, et al. The metabolic regulator PGC-1alpha links hepatitis C
virus infection to hepatic insulin resistance. Journal of hepatology.
2012;57(4):867-73.
37. Jung HJ, Kim YS, Kim SG, Lee YN, Jeong SW, Jang JY, et al. The impact
of pegylated interferon and ribavirin combination treatment on lipid
metabolism and insulin resistance in chronic hepatitis C patients. Cli-
nical and molecular hepatology. 2014;20(1):38-46.
38. Lacerda GS, Medeiros T, Rosario NFD, Peralta RHS, Cabral-Castro MJ,
Esberard EBC, et al. Exploring lipid and apolipoprotein levels in chronic
hepatitis C patients according to their response to antiviral treatment.
Clinical biochemistry. 2018;60:17-23.
39. Sun HY, Cheng PN, Tseng CY, Tsai WJ, Chiu YC, Young KC. Favouring
modulation of circulating lipoproteins and lipid loading capacity by di-
rect antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir tre-
atment against chronic HCV infection. Gut. 2018;67(7):1342-50.
40. Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, Chung RT. Hepatitis
C virus infection and its clearance alter circulating lipids: implications
for long-term follow-up. Hepatology. 2009;50(4):1030-7.
41. El Sagheer G, Soliman E, Ahmad A, Hamdy L. Study of changes in
lipid profile and insulin resistance in Egyptian patients with chronic
hepatitis C genotype 4 in the era of DAAs. The Libyan journal of me-
dicine. 2018;13(1):1435124.
Si desea citar nuestro artículo:
Esther Rey, Patricia Marañón y Águeda González-Rodríguez
El tratamiento con sofosbuvir mejora la resistencia a la
insulina inducida por el virus de la hepatitis C
An Real Acad Farm [Internet].
An. Real Acad. Farm. Vol. 87. Nº 1 (2021) · pp. 15 - 26
DOI: http://